HomeCompareCHFFF vs ABBV

CHFFF vs ABBV: Dividend Comparison 2026

CHFFF yields 4.48% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.1K in total portfolio value
10 years
CHFFF
CHFFF
● Live price
4.48%
Share price
$0.67
Annual div
$0.03
5Y div CAGR
-11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$160.77
Full CHFFF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CHFFF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHFFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHFFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHFFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHFFF
Annual income on $10K today (after 15% tax)
$380.60/yr
After 10yr DRIP, annual income (after tax)
$136.65/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,730.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHFFF + ABBV for your $10,000?

CHFFF: 50%ABBV: 50%
100% ABBV50/50100% CHFFF
Portfolio after 10yr
$64.2K
Annual income
$12,943.25/yr
Blended yield
20.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CHFFF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHFFF buys
0
ABBV buys
0
No recent congressional trades found for CHFFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHFFFABBV
Forward yield4.48%3.12%
Annual dividend / share$0.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-11.3%40.6%
Portfolio after 10y$23.6K$104.7K
Annual income after 10y$160.77$25,725.73
Total dividends collected$2.7K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CHFFF vs ABBV ($10,000, DRIP)

YearCHFFF PortfolioCHFFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,097$397.16$11,559$438.51$462.00ABBV
2$12,239$365.36$13,494$640.86$1.3KABBV
3$13,430$334.05$15,951$945.97$2.5KABBV
4$14,674$303.86$19,152$1,413.89$4.5KABBV
5$15,976$275.22$23,443$2,146.38$7.5KABBV
6$17,343$248.40$29,391$3,321.96$12.0KABBV
7$18,781$223.53$37,948$5,265.87$19.2KABBV
8$20,296$200.66$50,795$8,596.74$30.5KABBV
9$21,897$179.76$71,034$14,549.41$49.1KABBV
10$23,590$160.77$104,715$25,725.73$81.1KABBV

CHFFF vs ABBV: Complete Analysis 2026

CHFFFStock

China Everbright Environment Group Limited, provides environmental solutions worldwide. The company's Environmental Energy Project Construction and Operation segment constructs and operates food waste and leachate treatment, sludge treatment and disposal, methane-to-energy, fecal treatment, fly ash landfill, medical waste treatment, and solid waste treatment projects, as well as waste-to-energy plants. Its Greentech Project Construction and Operation segment constructs and operates integrated biomass utilization, hazardous and solid waste treatment, and solar energy and wind power projects, as well as offers environmental remediation services. The company's Environmental Water Project Construction and Operation segment constructs, upgrades, and operates waste water treatment, water supply, reusable water and sludge harmless treatment, sponge city construction, river-basin ecological restoration, waste water source heat pump, and leachate treatment projects. This segment also researches and develops water environment technologies and engineering projects. Its Others segment conducts environmental protection technology research and development projects; provides environmental related technological, and protection project equipment construction and installation services; designs environmental protection projects; and sells related equipment. This segment also offers waste sorting, renewable resources utilization, and sanitation operation services; sells energy-saving street lamps; and provides energy management contract projects. It also operates biomass electricity and heat cogeneration projects; and collects and treats municipal wastes. The company was formerly known as China Everbright International Limited and changed its name to China Everbright Environment Group Limited in September 2020. The company was incorporated in 1961 and is headquartered in Hong Kong, Hong Kong.

Full CHFFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CHFFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHFFF vs SCHDCHFFF vs JEPICHFFF vs OCHFFF vs KOCHFFF vs MAINCHFFF vs JNJCHFFF vs MRKCHFFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.